EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitHistorischer BeitragOpen Access · CC BY 4.0

Antipsychotic drugs at 75: the past, present, and future of psychosis management

Monty Lyman iD, Robert A McCutcheon iD

British Medical Bulletin · 22.09.2025 · 156 (1)

DOI: 10.1093/bmb/ldaf016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Medical Bulletin, online erschienen am 06.10.2025. Verfasst von Monty Lyman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Ln, Headington, Oxford OX3 7JX, United Kingdom. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders, Schizophrenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome Trust Clinical Research Career Development Fellowship, NIHR Oxford Health Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction The discovery of chlorpromazine in 1950 marked a turning point in psychiatry, and, for the first time, effective pharmacological treatments for psychosis became widely used. Over the following decades, antipsychotics became the cornerstone of schizophrenia treatment, yet their fundamental mechanism—dopamine D2 receptor antagonism—has remained largely unchanged. Now, 75 years on, novel drug classes and advances in mechanistic understanding are reshaping the field. Sources of data This review synthesizes findings from clinical trials, neurobiological research, and pharmacological studies, highlighting the evolution of antipsychotic treatment. Areas of agreement Antipsychotics reduce positive symptoms, but their efficacy for negative and cognitive symptoms is limited. Clozapine remains the gold standard for treatment-resistant schizophrenia. Areas of controversy The typical/atypical distinction is increasingly seen as outdated. The dopamine hypothesis, while central, does not fully explain schizophrenia. Growing points Emerging nondopaminergic treatments—such as the muscarinic agonist xanomeline-trospium—offer new therapeutic avenues. Areas timely for developing research Further research is needed to determine the clinical utility of nondopaminergic drugs, refine stratified treatment approaches, and integrate precision psychiatry into psychosis management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsPsychotic DisordersSchizophreniaHumansHistory, 20th CenturyHistory, 21st Century

Stichwörter der Autor:innen

antipsychoticsdopamineprecision psychiatrypsychosisschizophrenia

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Ln, Headington, Oxford OX3 7JX, United Kingdom.
  • Oxford Health NHS Foundation Trust, Warneford Hospital, Warneford Ln, Headington, Oxford OX3 7JX, United Kingdom.
  • Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, United Kingdom.

ORCID-Profile: Monty Lyman, Robert A McCutcheon

Förderung

  • Wellcome Trust
  • Wellcome Trust Clinical Research Career Development Fellowship
  • NIHR Oxford Health Biomedical Research Centre

Zitieren

APA

Lyman, M., & McCutcheon, R. A. (2025). Antipsychotic drugs at 75: the past, present, and future of psychosis management. British Medical Bulletin, 156(1). https://doi.org/10.1093/bmb/ldaf016

Vancouver

Lyman M, McCutcheon RA. Antipsychotic drugs at 75: the past, present, and future of psychosis management. British Medical Bulletin. 2025;156(1). doi:10.1093/bmb/ldaf016

BibTeX
@article{Lyman2025,
  author = {Lyman, Monty and McCutcheon, Robert A},
  title = {Antipsychotic drugs at 75: the past, present, and future of psychosis management},
  journal = {British Medical Bulletin},
  year = {2025},
  volume = {156},
  number = {1},
  doi = {10.1093/bmb/ldaf016}
}
Kostenlos starten →